~~<i id='8B84AF7C91'><strike id='8B84AF7C91'><tt id='8B84AF7C91'><pre id='8B84AF7C91'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

fashion

author：knowledge 2025-08-12 08:27:55 - browse：72

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： How to make the FDA’s new prescription one

focus

leisure time

hotspot

explore

focus

leisure time

DrewAngerer/GettyImagesVikingTherapeuticssaidTuesdaythatitscloselywatchedoralobesitydrughadsucceeded

WSS

How medical schools plan to diversify without affirmative action

How medical schools plan to diversify without affirmative action

FDA panel endorses Alnylam’s heart drug — after picking it apart

Study: Black kids more likely to die after surgery than white kids

Multiple sclerosis has subtypes with different best treatments: study

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

entertainment

fashion

focus

In Memoriam: Notable people who died in 2023

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

U.K. decision on ALS drug has neurologists, advocates up in arms

Medical leaders decry Supreme Court decision on affirmative action

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

State Dept. review finds Biden bears some blame for Afghanistan failures

Drug companies' payments and gifts affect physicians' prescribing

Alkermes shareholders re

Private equity could exacerbate cardiology's overuse problem, experts fear

leisure time

PEPFAR is under serious threat — and so is global health

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Medicare Advantage 2025 payments will dip, Biden administration says

Medicare Advantage 2025 payments will dip, Biden administration says

People with mental disorders often marry others with same

Mass General Brigham physicians react to latest merger step

hotspot

explore

focus

leisure time